e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2010
BioMed Realty Trust, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Maryland
|
|
1-32261
|
|
20-1142292 |
|
|
|
|
|
|
(State or Other Jurisdiction
of
Incorporation)
|
|
(Commission File No.)
|
|
(I.R.S. Employer
Identification No.) |
17190 Bernardo Center Drive
San Diego, California 92128
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (858) 485-9840
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement.
On January 11, 2010, BioMed Realty, L.P. (the “Operating Partnership”), the operating
partnership subsidiary of BioMed Realty Trust, Inc. (the “Company”), issued $180.0 million
aggregate principal amount of its 3.75% Exchangeable Senior Notes due 2030 (the “Notes”).
The net proceeds from the issuance of the Notes will be approximately
$174.1 million, after deducting initial purchasers’ discounts and
estimated offering expenses. The Operating Partnership intends to use
the net proceeds from the private offering to repay a portion of the
outstanding indebtedness under its $720.0 million unsecured line of
credit, which amount it may reborrow, and for other general corporate
and working capital purposes. The terms
of the Notes are governed by an indenture, dated January 11, 2010 (the “Indenture”), among the
Operating Partnership, as issuer, the Company, as guarantor, and U.S. Bank National Association, as
trustee. A copy of the Indenture, including the form of the Notes and Guarantee of the Company, the
terms of which are incorporated herein by reference, is attached as Exhibit 4.1 to this report. See
Item 2.03 below for additional information.
The Notes and the shares of common stock of the Company (“Common Stock”) issuable upon
exchange of the Notes have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”). The Operating Partnership offered and sold the Notes to the initial purchasers
of the Notes (the “Initial Purchasers”) in reliance on the exemption from registration provided by
Section 4(2) of the Securities Act. The Initial Purchasers then sold the Notes to qualified
institutional buyers pursuant to the exemption from registration provided by Rule 144A under the
Securities Act.
In connection with the issuance and sale of the Notes, the Operating Partnership and the
Company also entered into a registration rights agreement with Deutsche Bank Securities Inc.,
Credit Suisse Securities (USA) LLC, Morgan Stanley & Co. Incorporated and UBS Securities LLC, in
their capacity as representatives of the Initial Purchasers, dated January 11, 2010 (the
“Registration Rights Agreement”). A copy of the Registration Rights Agreement, the terms of which
are incorporated herein by reference, is attached as Exhibit 10.1 to this report.
Pursuant to the Registration Rights Agreement, the Company has agreed that it will:
| |
• |
|
file a shelf registration statement (which shall be an automatic shelf registration
statement if the Company is then a Well-Known Seasoned Issuer (“WKSI”)) with the Securities
and Exchange Commission by July 10, 2010 to cover resales of the underlying shares of
Common Stock that may be issuable upon exchange of the Notes; |
| |
| |
• |
|
if the Company is not a WKSI on July 10, 2010, use its reasonable efforts to have that
registration statement declared effective by July 10, 2010; and |
| |
| |
• |
|
use its reasonable efforts to keep the registration statement effective until the
earliest of (1) the 20th trading day immediately following the maturity date of January 15,
2030 and (2) the date on which there are no longer any “restricted” shares (within the
meaning of Rule 144 under the Securities Act) of Common Stock that have been issued upon
exchange of any Notes or Notes exchangeable for “restricted” shares of Common Stock. |
If the Company does not meet these deadlines, then, subject to certain exceptions, additional
interest will accrue on the Notes to be paid semi-annually in arrears at a rate per year equal to
0.25% of the principal amount of Notes to and including the 90th day following such registration
default and 0.50% of the principal amount thereafter, for the period during which the registration
default is not cured.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.
On January 11, 2010, the Operating Partnership issued $180,000,000 aggregate principal amount
of Notes. The purchase price paid by the Initial Purchasers was 97.0% of the principal amount
thereof, and the Initial Purchasers received discounts and commissions in an aggregate amount of
$4.5 million in connection with the issuance and sale of the Notes. The Notes are general unsecured
senior obligations of the Operating Partnership and rank equally in right of payment with all other
senior unsecured indebtedness of the Operating Partnership. Interest is payable on January 15 and
July 15 of each year beginning July 15, 2010 until the maturity date of January 15, 2030. The
Operating Partnership’s obligations under the Notes are fully and unconditionally guaranteed by the
Company.
The Notes bear interest at 3.75% per annum and may be exchanged for shares of Common Stock at
an initial exchange rate of 55.0782 shares per $1,000 principal amount of Notes. At the initial
exchange rate, the Notes are exchangeable for Common Stock at an exchange price of approximately
$18.16 per share, representing an approximately 20.0% premium over the last reported sale price of
the Common Stock on January 5, 2010, which was $15.13 per share.
Prior to January 21, 2015, the Operating Partnership may not redeem the Notes except to
preserve the Company’s status as a real estate investment trust. On or after January 21, 2015, at
the Operating Partnership’s option, the Notes are redeemable in cash, in whole or in part, at 100%
of the principal amount plus accrued and unpaid interest upon at least 30 days’ but not more than
60 days’ prior written notice to holders of the Notes.
The holders of the Notes have the right to require the Operating Partnership to repurchase the
Notes for cash, in whole or in part, on each of January 15, 2015, January 15, 2020 and January 15,
2025, and upon the occurrence of a designated event, in each case for a repurchase price equal to
100% of the principal amount of the Notes plus accrued and unpaid interest.
A “designated event” will be deemed to have occurred at the time that any of the following
occurs:
| |
• |
|
consummation of any transaction or event (whether by means of a share exchange or tender
offer applicable to the Common Stock, a liquidation, consolidation, recapitalization,
reclassification, combination or merger of the Company or a sale, lease or other transfer
of all or substantially all of the consolidated assets of the Company) or a series of
related transactions or events pursuant to which all of the outstanding shares of Common
Stock is exchanged for, converted into or constitutes solely the right to receive cash,
securities or other property more than 10% of which consists of cash, securities or other
property that are not, or upon issuance will not be, traded on a national securities
exchange; |
| |
| |
• |
|
any “person” or “group” (as such terms are used for purposes of Sections 13(d) and 14(d)
of the Securities Exchange Act of 1934, as amended, whether or not applicable), other than
the Operating Partnership or any majority-owned subsidiary of the Company or the Operating
Partnership or any employee benefit plan of the Company, the Operating |
| |
|
|
Partnership or such subsidiary, is or becomes the “beneficial owner,” directly or
indirectly, of more than 50% of the total voting power in the aggregate of all classes of
capital stock of the Company then outstanding entitled to vote generally in elections of
directors (for the avoidance of doubt the ownership of Operating Partnership units will not
be deemed to constitute beneficial ownership of capital stock of the Company); |
| |
• |
|
during any period of twelve consecutive months after January 11, 2010, persons who at
the beginning of such twelve-month period constituted the board of directors of the
Company, together with any new persons whose election was approved by a vote of a majority
of the persons then still comprising the board of directors who were either members of the
board of directors at the beginning of such period or whose election, designation or
nomination for election was previously so approved, cease for any reason to constitute a
majority of the board of directors of the Company; or |
| |
| |
• |
|
the Company (or any successor thereto permitted pursuant to the terms of the Indenture)
ceases to be the general partner of the Operating Partnership or ceases to control the
Operating Partnership; provided, however, that the pro rata distribution by the Company to
its stockholders of shares of its capital stock or shares of any of the Company’s other
subsidiaries will not, in and of itself, constitute a designated event for purposes of this
definition. |
If a transaction described in the first bullet under the definition of a “designated event”
above occurs on or prior to January 21, 2015 and a holder elects to exchange its Notes in
connection with such transaction, we will increase the applicable exchange rate for the Notes
surrendered for exchange by a specified number of additional shares of Common Stock as a “make
whole premium.”
Certain events are considered “Events of Default,” which may result in the accelerated
maturity of the Notes, including:
| |
• |
|
a default for 30 days in the payment of any installment of interest under the Notes; |
| |
| |
• |
|
a default in the payment of the principal amount or any repurchase price or redemption
price due with respect to the Notes, when the same becomes due and payable; |
| |
| |
• |
|
the Operating Partnership’s failure to deliver cash, Common Stock or a combination of
cash and Common Stock within 15 days after the due date upon an exchange of the Notes,
together with any cash due in lieu of fractional shares of Common Stock; |
| |
| |
• |
|
the Operating Partnership’s failure to comply with any of its other agreements in the
Notes or the Indenture upon receipt of notice of such default by the trustee or by holders
of not less that 25% in aggregate principal amount of the Notes then outstanding and the
failure to cure (or obtain a waiver of) such default within 60 days after receiving notice
of such failure; |
| |
| |
• |
|
failure to pay any indebtedness for money borrowed by the Operating Partnership, the
Company, any subsidiary in which the Operating Partnership has invested at least $25
million in capital (a “Significant Subsidiary”), in an outstanding principal amount in |
| |
|
|
excess of $25 million at final maturity or upon acceleration after the expiration of any
applicable grace period, which indebtedness is not discharged, or such default in payment or
acceleration is not cured or rescinded, within 30 days after written notice to the Operating
Partnership from the trustee (or to the Operating Partnership and the trustee from holders
of at least 25% in principal amount of the outstanding Notes); |
| |
• |
|
the Operating Partnership’s failure to provide timely notice of a designated event; or |
| |
| |
• |
|
certain events of bankruptcy, insolvency or reorganization or court appointment of a
receiver, liquidator or trustee of the Operating Partnership, the Company or any
Significant Subsidiary or any substantial part of their respective property. |
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Items 1.01 and 2.03 of this report is incorporated herein by
reference.
Item 8.01 Other Events.
On January 5, 2010, the Company announced that the Operating Partnership commenced a private
placement to qualified institutional buyers of the Notes. The press release announcing the
commencement of the private placement is filed as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
On January 5, 2010, the Company announced that the Operating Partnership priced the private
placement of the Notes. The press release announcing the pricing of this private placement is filed
as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
On January 11, 2010, the Company announced that the Operating Partnership closed the private placement of the Notes,
including the exercise in full of the initial purchasers’ over-allotment option. The press release announcing
the closing of this private placement is filed as Exhibit 99.3 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibits are filed herewith:
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
4.1
|
|
Indenture, dated January 11, 2010, among BioMed Realty, L.P., BioMed
Realty Trust, Inc. and U.S. Bank National Association, as trustee,
including the form of 3.75% Exchangeable Senior Notes due 2030. |
10.1
|
|
Registration Rights Agreement, dated January 11, 2010, among BioMed
Realty Trust, Inc., BioMed Realty, L.P., Deutsche Bank Securities
Inc., Credit Suisse Securities (USA) LLC, Morgan Stanley & Co.
Incorporated and UBS Securities LLC. |
99.1
|
|
Press release issued by BioMed Realty Trust, Inc. on January 5, 2010. |
99.2
|
|
Press release issued by BioMed Realty Trust, Inc. on January 5, 2010. |
99.3
|
|
Press release issued by BioMed Realty Trust, Inc. on January 11, 2010. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| Date: January 11, 2010 |
BIOMED REALTY TRUST, INC.
|
|
| |
By: |
/s/ KENT GRIFFIN
|
|
| |
|
Name: |
Kent Griffin |
|
| |
|
Title: |
President, Chief Operating Officer and
Chief Financial Officer |
|
Exhibit Index
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
4.1
|
|
Indenture, dated January 11, 2010, among BioMed Realty, L.P., BioMed
Realty Trust, Inc. and U.S. Bank National Association, as trustee,
including the form of 3.75% Exchangeable Senior Notes due 2030. |
10.1
|
|
Registration Rights Agreement, dated January 11, 2010, among BioMed
Realty Trust, Inc., BioMed Realty, L.P., Deutsche Bank Securities
Inc., Credit Suisse Securities (USA) LLC, Morgan Stanley & Co.
Incorporated and UBS Securities LLC. |
99.1
|
|
Press release issued by BioMed Realty Trust, Inc. on January 5, 2010. |
99.2
|
|
Press release issued by BioMed Realty Trust, Inc. on January 5, 2010. |
99.3
|
|
Press release issued by BioMed
Realty Trust, Inc. on January 11, 2010. |